Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Immune checkpoint inhibitors are a new class of cancer therapeutics that have
demonstrated striking successes in a rapid series of clinical trials. Consequently, these …

Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Abstract Background Immune checkpoint inhibitors (ICIs) are available for first-and further
lines of treatment of patients with advanced non–small-cell lung cancer (NSCLC). These …

Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal
antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging …

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event
that requires prompt identification and management. Although often referred to as …

Background Significant improvement in survival outcome with the programmed death 1 (PD-
1)/programmed death ligand 1 (PD-L1) inhibitors has been shown in advanced non-small …

Lung cancer is the leading cause of cancer deaths worldwide, mainly because it is usually in
the advanced stage at the time of diagnosis. Although great progress has been made in the …